Safety and efficacy of house dust mite subcutaneous immunotherapy (interim analysis of post-marketing surveillance from 2016 to 2019)

[PE22-8] Safety and efficacy of house dust mite subcutaneous immunotherapy (interim analysis of post-marketing surveillance from 2016 to 2019)

Hiroki Matsuhara, Takeru Sugawara, Yuriko Maekawa, Remi Hashimoto, Keiichi Tanigchi (Torii Pharmaceutical Co., Ltd., Japan)

The password to see abstracts was announced to registrants by email.